Subscribe to PLMJ’s newsletters to receive the most up-to-date legal insights and our invitations to exclusive events.
We are looking for people who aim to go further and face the future with confidence.
Subscribe to PLMJ’s newsletters to receive the most up-to-date legal insights and our invitations to exclusive events.
We are looking for people who aim to go further and face the future with confidence.
National Commission of Pharmacy and Therapeutics guidance note 19/March/2025
The National Commission of Pharmacy and Therapeutics (Comissão Nacional de Farmácia e Terapêutica – “CNFT”) approved Guidance Note 19/March/2025 on the use of medicines under off-label conditions on 14 March 2025.
Off-label use – the use of a medicine for an unapproved indication or in an unapproved age group, dosage or route of administration – is becoming increasingly important in clinical practice. This importance is justified by the complexity, length of time and financial cost associated with the process of technical and scientific evaluation of a medicine or a new therapeutic indication. The off-label use of medicines thus allows medicines to be used to treat pathologies for which the medicine does not have an approved therapeutic indication.
Off-label prescribing has become increasingly common and there are no specific regulations governing the practice. For this reason, the CNFT has considered it necessary to make a number of proposals, the main aim of which is to help standardise the actions of the Local Pharmacy and Therapeutics Commissions (Comissões de Farmácia e Terapêutica Locais – “Local CFTs”) when they receive requests for authorisation to use off-label medicines.
The CNFT therefore proposes:
The use of off-label medicines is restricted and depends on meeting all of the following conditions:
The CNFT also proposes that local CFTs classify applications for off-label use into three different groups, depending on the specific case and conditions of use:
In addition to the conditions on which the off-label use of medicines depends and the categorisation of each use, the CNFT also indicates the conditions that must be met by the medicine supply chain in order to issue the prescription in question: